Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sublingual immunotherapy in dust mite allergy

Trial Profile

Sublingual immunotherapy in dust mite allergy

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Perennial allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Mar 2009 Efficacy results have been published in the proceedings of the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 17 Mar 2009 Safety and tolerability results have been published in the proceedings of the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 21 Nov 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top